uniQure (QURE) Ests and PT Cut After Dropping Glybera - Jefferies
Get Alerts QURE Hot Sheet
Rating Summary:
23 Buy, 3 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 41
Join SI Premium – FREE
Jefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to the Buy rating.
QURE no longer pursuing U.S. approval of Glybera does not come as a total surprise given frustrating progress to date & disappointing EU launch. This underscores yet-tobe proven commercial potential of gene therapies.
Revenues in 3Q15 were ~€3.2M but QURE stated that it is taking an impairment charge related to a reduction in the number of patients that can be treated with Glybera for lipoprotein lipase deficiency (LPLD). Cash of ~€215M at end-3Q15 should be sufficient into ~2018
Upcoming clinical events include: (1) Ph1/2 preliminary data from 2 pts for AMT-060 in hemophilia B in Jan. 2016 & preliminary data from 5 pts in the low-dose cohort in 1H16; (2) regulatory pathway for AMT-060 & AMT-110 to be established in 2016/early-2017; (3) 30-mo follow-up Ph1/2 data for AMT-110 in Sanfilippo B in 2016; (4) IND-enabling studies for Huntington's Disease & hemophilia A to begin in 2016; (5) at least 1 new program each in liver & CNS to be nominated in 2016; and (6) validation testing of 4D Synthetic AAV candidates to begin in 2016.
For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.
Shares of uniQure BV closed at $18.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Raia Drogasil SA (RADL3:BZ) to Buy
- Caribou Biosciences Inc. (CRBU) PT Raised to $24 at H.C. Wainwright on better results and estimates
- Redburn-Atlantic Downgrades MongoDB (MDB) to Sell, 'consensus expectations are overly optimistic at current valuation levels'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!